A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem, Inc.
Verastem, Inc.
Hoffmann-La Roche
Bristol-Myers Squibb
Genmab
Genmab
Astellas Pharma Inc
Synthekine
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Xencor, Inc.
PMV Pharmaceuticals, Inc
Mayo Clinic
NeoImmuneTech
Revolution Medicines, Inc.
H. Lee Moffitt Cancer Center and Research Institute
Neonc Technologies, Inc.
AbbVie
Intima Bioscience, Inc.
Providence Health & Services
University of Michigan Rogel Cancer Center
GlaxoSmithKline
University of California, Davis
VA Office of Research and Development
Takeda
Big Ten Cancer Research Consortium
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Linnaeus Therapeutics, Inc.
Inhibrx Biosciences, Inc
SignalChem Lifesciences Corporation
VM Oncology, LLC
Transgene
Tango Therapeutics, Inc.
Roswell Park Cancer Institute
BerGenBio ASA
Dragonfly Therapeutics
Krystal Biotech, Inc.
BioNTech SE
M.D. Anderson Cancer Center
Daiichi Sankyo
Eli Lilly and Company
BioInvent International AB
Vyriad, Inc.
Immuneering Corporation
University of Nebraska
NuCana plc
PDC*line Pharma SAS
OncoC4, Inc.
Mural Oncology, Inc
Rapa Therapeutics LLC